EDISON, N.J., May 24, 2018 (GLOBE NEWSWIRE) — ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical aggregation focused on the development and commercialization of ameliorative drugs for the analysis of hepatitis B virus (HBV) appear today, a about-face breach of its accepted stock, $0.0001 par value, at a arrangement of 1 for 8, able May 25, 2018 (the “Effective Date”). The company’s accepted banal will activate trading on a split-adjusted base back the markets accessible on May 29, 2018 beneath the absolute trading attribute “CTRV.”
The about-face banal breach is primarily advised to accompany the aggregation into acquiescence with the minimum bid amount claim for advancement its advertisement on the Nasdaq Capital Market. The new CUSIP cardinal for the accepted banal afterward the about-face breach will be 21234W 202.
As a aftereffect of the about-face split, anniversary 8 pre-split shares of accepted banal outstanding will automatically amalgamate into one new allotment of accepted banal after any activity on the allotment of the holders, and the cardinal of outstanding accepted shares will be bargain from about 85.5 actor shares to about 10.7 actor shares. Proportionate adjustments will be fabricated to the about-face and exercise prices of the company’s outstanding warrants, banal options and to the cardinal of shares issued and issuable beneath the company’s disinterestedness allurement plans. The accepted banal issued pursuant to the about-face banal breach will abide absolutely paid and non-assessable. The about-face banal breach will not affect the par amount of the accepted stock.
On January 2, 2018, the lath of admiral of the aggregation accustomed the about-face banal split, accountable to actor approval. On March 9, 2018, a majority of the company’s shareholders accustomed giving the Lath arbitrary ascendancy to achieve the about-face banal split. The Lath accustomed the about-face banal breach on a one for eight arrangement on May 14, 2018.
The about-face banal breach will affect all stockholders analogously and will not adapt any stockholder’s allotment absorption in the company’s equity, except to the admeasurement that the about-face banal breach would aftereffect in a stockholder owning a apportioned share. Holders of accepted banal contrarily advantaged to a apportioned allotment as a aftereffect of the about-face banal breach will accept a banknote acquittal in lieu of such apportioned share. The company’s alteration agent, Philadelphia Banal Transfer, Inc. (PST), will act as advantageous abettor for the about-face banal split. PST will accommodate stockholders of almanac captivation certificates apery pre-split shares of the company’s accepted banal as of the able date, a letter of assignment accouterment instructions for the barter of shares. Registered stockholders captivation pre-split shares of the company’s accepted banal electronically in book-entry anatomy are not appropriate to booty any activity to accept post-split shares. Stockholders owning shares via a broker, bank, assurance or added appointee will accept their positions automatically adapted to reflect the about-face banal split, accountable to such broker’s accurate processes, and will not be appropriate to booty any activity in affiliation with the about-face banal split. Added advice about the about-face banal breach can be begin in the company’s absolute proxy account (Form DEF 14A) filed with the Securities and Barter Commission on January 24, 2018 accessible chargeless of allegation at the SEC’s website www.sec.gov or at the company’s website www.contravir.com. Philadelphia Banal Transfer, Inc. can be accomplished by buzz at (484) 416-3124 or mail at 2320 Haverford Rd., Suite 230, Ardmore, PA 19003
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical aggregation focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially alleviative analysis for hepatitis B virus (HBV). The aggregation is developing two atypical anti-HBV compounds with commutual mechanisms of action. TXL™, a nucleoside analog lipid prodrug of tenofovir (TFV), is advised to bear college hepatic intracellular concentrations of the alive tenofovir breed (tenofovir diphosphate) while abbreviation concentrations of tenofovir alfresco the liver, causing beneath astray toxicities and side-effects. CRV431, the added anti-HBV compound, is a next-generation cyclophilin inhibitor with a atypical anatomy that increases its authority and careful basis adjoin HBV. In vitro and in vivo studies accept appropriately far approved that CRV431 reduces HBV DNA and added viral proteins, including apparent antigen (HBsAg). For added advice visit www.contravir.com
Forward Looking Statements
Certain statements in this columnist absolution are advanced aural the acceptation of the Private Securities Litigation Reform Act of 1995. These statements may be articular by the use of advanced words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” amid others. These advanced statements are based on ContraVir’s accepted expectations and absolute after-effects could alter materially. There are a cardinal of factors that could account absolute contest to alter materially from those adumbrated by such advanced statements. These factors include, but are not bound to, abundant competition; our adeptness to abide as a activity concern; our charge for added financing; uncertainties of apparent aegis and litigation; uncertainties with account to diffuse and big-ticket analytic trials, that after-effects of beforehand studies and trials may not be predictive of approaching balloon results; uncertainties of government or third affair payer reimbursement; bound sales and business efforts and assurance aloft third parties; and risks accompanying to abortion to access FDA clearances or approvals and contravention with FDA regulations. As with any biologic candidates beneath development, there are cogent risks in the development, authoritative approval, and commercialization of new products. There are no guarantees that approaching analytic trials discussed in this columnist absolution will be completed or successful, or that any artefact will accept authoritative approval for any adumbration or prove to be commercially successful. ContraVir does not undertake an obligation to amend or alter any advanced statement. Investors should apprehend the accident factors set alternating in ContraVir’s Form 10-KT for the year concluded December 30, 2017 and added alternate letters filed with the Securities and Barter Commission.
For added information, amuse contact:
Sharen Pyatetskaya Director of Investor [email protected]; (732) 902-4028
This Is Why Sec Form Def 6a Instructions Is So Famous! | Sec Form Def 6a Instructions – sec form def 14a instructions
| Delightful to my own blog site, on this moment I’ll show you about sec form def 14a instructions